Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Income from Continuing Operations (2016 - 2025)

Cardiff Oncology's Income from Continuing Operations history spans 15 years, with the latest figure at 7215000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 38.78% year-over-year to 7215000.0; the TTM value through Dec 2025 reached 45856000.0, down 1.02%, while the annual FY2025 figure was 45856000.0, 1.02% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 7215000.0 at Cardiff Oncology, up from 11258000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5442000.0 in Q1 2021 and bottomed at 13942000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 10225000.0 (2022), against an average of 10167050.0.
  • The largest annual shift saw Income from Continuing Operations tumbled 103.49% in 2022 before it skyrocketed 38.78% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 9526000.0 in 2021, then grew by 1.41% to 9392000.0 in 2022, then increased by 0.72% to 9324000.0 in 2023, then dropped by 26.39% to 11785000.0 in 2024, then surged by 38.78% to 7215000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Income from Continuing Operations are 7215000.0 (Q4 2025), 11258000.0 (Q3 2025), and 13942000.0 (Q2 2025).